Innovation at Stallergenes Greer
Innovation lies at the heart of our ethos and day-to-day activities
The frontiers of medicine are always shifting. At Stallergenes Greer, we are helping to accelerate that progress in the treatment of allergies.
Having pioneered the sublingual immunotherapy segment, we aim to search for and develop new therapeutic solutions that meet the needs of allergy patients worldwide. Today, just one of our several AIT ranges provides patient relief from the substances that trigger more than 80% of respiratory allergies.
Driven by patients’ needs, our research model includes establishing a strong scientific basis for our work, understanding the mechanisms of action and documenting the quality of our products through molecular characterisation. This, in turn, relies on evidence-based, clinical data to demonstrate the safety and effectiveness of our treatments.
Today, there are more than 100 identified allergens, grouped into main families:
- Pneumallergens or respiratory allergens (such as house dust mites, pollen and plant derived allergens, dander – including cat and dog hair – mould and yeast)
- Hymenoptera venom
- Food allergens
- Chemical or medicinal allergens
- Contact allergens